Compare iShares US Power Infrastructure ETF (POWR) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares US Power Infrastructure ETF vs Repligen Corporation Common Stock — how do they compare? iShares US Power Infrastructure ETF trades at $24.82 (market cap $451.52M), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 25× iShares US Power Infrastructure ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, iShares US Power Infrastructure ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares US Power Infrastructure ETF for 19 Days and Repligen Corporation Common Stock for 0 Days on average.
| POWR | RGEN | |
|---|---|---|
Market Cap | $451.52M | $11.31B |
Volume | 242,554 | 1,216,919 |
Sector | Sector/Thematic | Health |
52-Week High | $28.22 | $194.57 |
52-Week Low | $23.20 | $102.87 |
Typical Hold Time | 19 Days | 0 Days |
Enterprise Value | — | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
POWR trades at $25.68, up 0.75% with a bullish technical signal from moving averages. The company reported $256.66M revenue in 2014 but posted a net loss of -$6.99M, with negative EBITDA of -$952K. Cash flow trends show volatility, with 2014 net cash flow at -$17.14M. The stock faces fundamental challenges despite technical strength, with debt-to-asset ratio at 7.09 indicating high leverage.
The outlook remains mixed with technical indicators supporting near-term upside, but fundamental weaknesses in profitability and cash flow generation pose significant risks. Investment opportunity exists if operational improvements materialize, while current financial metrics suggest caution for value-oriented investors.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares US Power Infrastructure ETF
iShares U.S. Power Infrastructure ETF seeks exposure to U.S. companies involved in power infrastructure. Its holdings may include electric utilities, transmission and distribution businesses, and electrical equipment providers.
Read more on POWR →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
